RSCM
Rock Springs Capital Management Portfolio holdings
AUM
$1.6B
This Quarter Return
+15.53%
1 Year Return
+25.98%
3 Year Return
+194.74%
5 Year Return
+336.76%
10 Year Return
+2,199.29%
AUM
$2.17B
AUM Growth
+$2.17B
(+10%)
Cap. Flow
+$20.8M
Cap. Flow
% of AUM
0.96%
Top 10 Holdings %
Top 10 Hldgs %
27.68%
Holding
162
New
13
Increased
39
Reduced
22
Closed
14
Top Buys
| 1 |
UnitedHealth
UNH
|
$28.4M |
| 2 |
iRhythm Technologies
IRTC
|
$20M |
| 3 |
Puma Biotechnology
PBYI
|
$17.2M |
| 4 |
Molina Healthcare
MOH
|
$10.9M |
| 5 |
PTLA
Portola Pharmaceuticals, Inc.
PTLA
|
$9.95M |
Top Sells
| 1 |
AGN
Allergan plc
AGN
|
$37.9M |
| 2 |
Humana
HUM
|
$31.9M |
| 3 |
Hologic
HOLX
|
$19.1M |
| 4 |
Madrigal Pharmaceuticals
MDGL
|
$11.9M |
| 5 |
Medtronic
MDT
|
$11.9M |
Sector Composition
| 1 | Healthcare | 80.49% |
| 2 | Financials | 3.75% |
| 3 | Consumer Discretionary | 0.9% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Vertex Pharmaceuticals
VRTX
$102B
| $23M | 1.06% |
151,500
+22,500
| +17% | +$3.42M |
|
27
Mersana Therapeutics
MRSN
$34.8M
| $23M | 1.06% |
1,330,000
-197,893
| -13% | -$3.42M |
|
28
Johnson & Johnson
JNJ
$429B
| $22.8M | 1.05% |
175,000
| – | – |
|
29
Theravance Biopharma
TBPH
$691M
| $22.1M | 1.02% |
644,400
+44,400
| +7% | +$1.52M |
|
30
Galapagos
GLPG
$2.06B
| $21.8M | 1% |
214,000
-7,500
| -3% | -$763K |
|
31
Thermo Fisher Scientific
TMO
$183B
| $20.8M | 0.96% |
110,000
| – | – |
|
32
Edwards Lifesciences
EW
$47.7B
| $20.8M | 0.96% |
190,001
| – | – |
|
33
Exact Sciences
EXAS
$9.33B
| $20.6M | 0.95% |
437,400
-100
| -0% | -$4.71K |
|
34
Insmed
INSM
$30.3B
| $20.3M | 0.94% |
650,000
+182,000
| +39% | +$5.68M |
|
35
Incyte
INCY
$17B
| $20.2M | 0.93% |
173,000
| – | – |
|
36
Prothena Corp
PRTA
$452M
| $20M | 0.92% |
309,500
| – | – |
|
|
37
iRhythm Technologies
IRTC
$5.67B
| $20M | 0.92% |
+386,000
| New | +$20M |
|
|
AFAM
38
DELISTED
Almost Family Inc
AFAM
| $19.4M | 0.9% |
362,000
| – | – |
|
39
Danaher
DHR
$143B
| $19.3M | 0.89% |
225,000
| – | – |
|
|
40
Medtronic
MDT
$118B
| $19.2M | 0.89% |
247,364
-152,636
| -38% | -$11.9M |
|
|
CLVS
41
DELISTED
Clovis Oncology, Inc.
CLVS
| $19.1M | 0.88% |
231,500
| – | – |
|
42
Collegium Pharmaceutical
COLL
$1.25B
| $18.9M | 0.87% |
1,805,000
+6,805
| +0.4% | +$71.4K |
|
|
BCR
43
DELISTED
CR Bard Inc.
BCR
| $18.4M | 0.85% |
57,500
| – | – |
|
44
Jazz Pharmaceuticals
JAZZ
$7.99B
| $18.1M | 0.83% |
123,700
| – | – |
|
45
Willis Towers Watson
WTW
$31.9B
| $17.7M | 0.82% |
115,000
+5,000
| +5% | +$771K |
|
|
PTLA
46
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
| $17.5M | 0.81% |
323,800
+184,100
| +132% | +$9.95M |
|
47
FibroGen
FGEN
$48.4M
| $17.5M | 0.81% |
325,000
+45,000
| +16% | +$2.42M |
|
|
WMGI
48
DELISTED
Wright Medical Group Inc
WMGI
| $17.3M | 0.8% |
670,000
| – | – |
|
|
AVXS
49
DELISTED
AveXis, Inc. Common Stock
AVXS
| $16.9M | 0.78% |
175,000
| – | – |
|
50
Biogen
BIIB
$20.8B
| $16.6M | 0.77% |
53,000
| – | – |
|